Monday, October 24, 2016 11:58:39 PM
Friday, 21 Oct 2016 | 2:44 PM ET | 02:54
Beaten-down biotech stocks could be set for a turnaround after Election Day, according to one strategist.
The Nasdaq Biotech ETF, the IBB, is down 21 percent year to date, and down just over 30 percent since hitting an all-time-high last July, but Stacey Gilbert of Susquehanna says a "relief rally" could be imminent.
"The big event, clearly, for the biotech space right now is the election," Gilbert said Friday on CNBC's "Power Lunch."
She noted that if Democratic nominee Hillary Clinton were to win the election and the Democrats were to sweep the House, it could be bad for the biotech space. However, with the likelihood of an all-Democratic house slim, she does expect to see a 3 to 5 percent rally for the group of stocks in the next few weeks.
"If you look at how the biotech sector has been under pressure for, let's say, the past month, you've also seen the probability that the Dems could sweep, increase during this period," Gilbert said. The likelihood of such an event is low, but would give way to a massive pullback — another 9 to 11 percent, Gilbert projects — "on that news alone."
Democratic nominee Hillary Clinton's remarks about drug pricing in late 2015, regarding Martin Shkreli's Turing Pharmaceuticals, and this year, related to drug manufacturer Mylan's price increase of its EpiPen product, both spurred lags in biotech stocks.
Eddy Elfenbein, editor of the Crossing Wall Street blog, said Friday on "Power Lunch" that Clinton's remarks about regulating drug prices have negatively impacted biotech names.
"It's been a really difficult year for the biotechs — the IBB still a third off its high from 2015, and clearly there's a lot of political risk; people are worried about what would happen with a Clinton victory," Elfenbein said.
"I think in the near term, until the election, there's still going to be a cloud over biotech. However, once we get past that, I think things look pretty good."
Elfenbein noted he likes the IBB "after Election Day" because he likes the valuations in biotech right now, and he predicts actually regulating drug pricing and passing legislation, as opposed to simply speaking about it during the campaign season, is much more difficult.
"Attacking the issue of pricing … it's a popular bumper sticker, but actually attacking the issue is much more complicated," he said.
http://www.cnbc.com/2016/10/24/beaten-down-biotech-shares-could-see-a-monster-relief-rally-after-election-day.html
Back to top
View user's profile Send private message
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM